Last updated 2026-06-18
- Raised funding round, Nov 2017
Total raised
—
Last: 2017-11
Stage
Seed
Founded
2017
Headcount
6
HQ
Yokne'am Illit, Israel
Sector
Health Tech & Life Sciences
About
NeurOptic's lead product for glaucoma is based on an FDA-approved drug indicated as therapy for neurodegenerative disease. NeurOptic is developing an ophthalmic formulation for glaucoma treatment established on the prolonged residence time of a monoamine oxidase inhibitor on the ocular surface and providing sustained delivery and constant effect of the drug for two months. Preliminary pre-clinical studies showed that the novel topical treatment of NeurOptic's product exerted a significant effect on high levels of intraocular pressure and may prevent neuronal damage in the eye.
Funding history · 1 round · — total
2017-11
Undisclosed
Q&A
- What is NeurOptic's primary focus?
- NeurOptic is focused on developing therapy for glaucoma, specifically an ophthalmic formulation based on an FDA-approved drug for neurodegenerative disease.
- When was NeurOptic founded?
- NeurOptic was founded in April 2017.
- What is the current status of NeurOptic?
- NeurOptic is currently inactive, having ceased operations in April 2018.
- What was NeurOptic's last funding round?
- NeurOptic's last funding round occurred in November 2017, with Youdim Pharmaceuticals as an investor.
- What is the product stage of NeurOptic's offering?
- NeurOptic's product is in the R&D stage.
- Does NeurOptic hold any patents?
- Yes, NeurOptic holds 1 patent.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2C
Highlights
1 Patents
Tags
pharma-companiesglaucomaeye-diseasesophthalmologypharmaceuticals
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2017-4 |
|---|---|
| Employees (exact) | 6 |
| Status reason | Non Active, Apr 2018 ceased to operate |